These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 18326949)

  • 21. [Treatment of dyslipidemia in clinical practice].
    Paragh G; Harangi M
    Orv Hetil; 2006 Mar; 147(9):389-94. PubMed ID: 16619956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low HDL-C: a secondary target of dyslipidemia therapy.
    Rosenson RS
    Am J Med; 2005 Oct; 118(10):1067-77. PubMed ID: 16194634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of dyslipidemia in diabetes.
    Solano MP; Goldberg RB
    Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
    Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
    Kastelein JJ
    Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.
    Ghandehari H; Kamal-Bahl S; Wong ND
    Am Heart J; 2008 Jul; 156(1):112-9. PubMed ID: 18585505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of intensive statin therapy in the elderly.
    Maroo BP; Lavie CJ; Milani RV
    Am J Geriatr Cardiol; 2008; 17(2):92-100. PubMed ID: 18326948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
    Vaverková H
    Vnitr Lek; 2007 Apr; 53(4):421-7. PubMed ID: 17578178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients.
    Miller AE; Hansen LB; Saseen JJ
    Pharmacotherapy; 2008 May; 28(5):553-61. PubMed ID: 18447653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapy of dyslipidemia in post-infarction: state of the art].
    Borgia MC; Nardi M; Da Ros S; Castellano V
    Clin Ter; 2007; 158(6):523-32. PubMed ID: 18265719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dyslipidemia control in indigent patients receiving medication assistance compared with insured patients.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2008 May; 28(5):562-9. PubMed ID: 18447654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Achieving cholesterol goals. Current and future drug therapies.
    Jones PH
    Postgrad Med; 2003 Aug; 114(2 Suppl):14-21. PubMed ID: 19667635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
    Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
    Crespo-Leiro MG; Paniagua MJ; Marzoa R; Grille Z; Naya C; Flores X; Rodriguez JA; Mosquera V; Franco R; Castro-Beiras A
    Transplant Proc; 2008 Nov; 40(9):3060-2. PubMed ID: 19010194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment with hydroxymethylglutaryl coenzyme-A-reductase inhibitors in elderly patients: is it necessary?].
    Alexa ID; Panaghiu L; Ungureanu G
    Rev Med Chir Soc Med Nat Iasi; 2005; 109(4):721-6. PubMed ID: 16610166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
    Goumas GS
    Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Niacin's role in the statin era.
    Brooks EL; Kuvin JT; Karas RH
    Expert Opin Pharmacother; 2010 Oct; 11(14):2291-300. PubMed ID: 20569085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.